Member Info for Timster

Could have:

- TU including S&S
- validation complete, obviously with S&S
- confirmed lfd supplier of choice in UK and the world
- MHRA replies to clinical trial of AVA6000
- Bruker validate BAMS with the workflow on thier machines.

Lot going on!

Also loads of collabs:
Stem cell affimer covid treatment
Waste water sensors

And see DOH Twitter for more:)

You called it mortgage, incredible!!

from interim Q&A:
Q: Could you please give an explanation of Cytiva's role in the manufacture of the LFD? it was initially indicated that they would manufacture, but this hasn't been mentioned in subsequent news regarding BBI/Abingdon. If so, will they manufacture for US markets only?
A: Cytiva manufacture materials to make the strip, provide nitro cellulose strip and not the finished LFD. Manufacturers are BBI and ABDX, etc etc. Raw materials from Cytiva then the kitting by BBI and ABDX

Who are you???
Holding up well after QD weekend revelations :) :)

Who could it be making up the shortfall after surescreen?
I can't think of any UK tests in development?

If I were you I'd sell gkb avacta is obvioisly not for you. With thier desire to create the best test in the world.

Not bad at all 500m looks like the 190m bib was cancelled as they were direct awarding these instead.
Next up Abakta.....

20% rise for us then...

You can stop dripping now, literally no one cares....

I've got one ..... quickdraw....

Go on, go on, tell us more??

Dyou know of anything that has happened In the last year??? Please help us QD?

Oh my god you're still going.....

Let it never be said again that this board has gone to rack and ruin! Incredible work QD, probably the most pointless piece of research anyone has ever done into Avacta. No doubt our sp will crash after that bombshell you feckin wierdo!

Hmmmm, how VERY interesting ..........

1000% maaaaattttt daaaaaamon just said that too (on another thread)

Depends very much on what RNS's we get.
Who knows Sir Al might have another collaboration to tell us about.
As has been said it will be interesting if the delayed TU contains details of income recieved from these collaborations and of course the S&S figures.
From the last RNS:
The Company looks forward to providing the market with a detailed business update later this month once definitive clinical data from the lateral flow test evaluation is available.

So that next week or the week after.

@livedata I know that's exactly what I posted??

We are very focused on LFT (for obvious reasons)

The MHRA have had 6 weeks to mull over the AVA6000 submission now:
"We expect to receive feedback from the MHRA (Medicines and Healthcare products Regulatory Agency) on the Clinical Trial Application by February 2021. Dosing of first patients will commence when we have responded to that feedback and received approval to proceed. I look forward to updating the market on the detailed timing in due course."

AND Bruker have had thier hands (officially) on BAMS for 2 and a half weeks:
"Our objective is to work with Bruker and our clinical partners to deliver an effective and high throughput assay protocol, that can be applied in the clinical setting, with the required sensitivity and specificity and CE/FDA approvals to provide a useful additional diagnostic tool in the fight against the coronavirus."

Exciting times ahead....!

I'd only noticed that wording I mentioned after rereading the RNS today:
clinical EVALUATION is currently happening in Europe. Once complete clinical VALIDATION will start in UK and Europe.

Got to pass porton down validation to be the sovereign test. Don't think they'll use the European hospital data.

I was thinking the porton down piece has also been progressing but just can't be reported. But who knows!